Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4050176 | 0.88 | CCR2 (0.43) | KMT2AMEN1SIGMAR1OPRM1OPRL1 | |
| SCHEMBL4054730 | 0.88 | ACKR3 (0.50) | ACKR3KMT2AALDH1A1MEN1SIGMAR1 | |
| SCHEMBL4048372 | 0.86 | NPC1 (0.42) | ACKR3KMT2AALDH1A1MEN1SIGMAR1 | |
| SCHEMBL4048579 | 0.86 | KMT2A (0.47) | ACKR3KMT2AALDH1A1MEN1SIGMAR1 | |
| SCHEMBL4048369 | 0.85 | NPC1 (0.41) | ACKR3KMT2AALDH1A1MEN1SIGMAR1 | |
| SCHEMBL4052294 | 0.83 | ACKR3 (0.48) | ACKR3KMT2AALDH1A1MEN1SIGMAR1 | |
| SCHEMBL4054571 | 0.83 | ACKR3 (0.49) | ACKR3KMT2AALDH1A1MEN1PKM | |
| SCHEMBL4050182 | 0.82 | KMT2A (0.51) | ACKR3KMT2AALDH1A1MEN1OPRM1 | |
| SCHEMBL4048882 | 0.82 | MAPT (0.44) | ACKR3KMT2AALDH1A1SIGMAR1OPRM1 | |
| SCHEMBL4045470 | 0.82 | ACKR3 (0.48) | ACKR3KMT2AALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1751088-B1 | OXO-SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2014-10-08 | — | — | EP | claimed |
| EP-1751088-B1 | OXO-SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2014-10-08 | — | — | EP | disclosed |
| US-7476763-B2 | Oxo-substituted cyclohexyl-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2009-01-13 | — | — | US | disclosed |
| US-20070088034-A1 | Oxo-substituted cyclohexyl-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088034-A1 | Oxo-substituted cyclohexyl-1,4-diamine compounds | AOC1, ODC1, OTC | ACKR3 3574/4885KMT2A 3911/4885ALDH1A1 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.